Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.

The salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infect...

Full description

Bibliographic Details
Main Authors: Christian Pedersen, Anatoly Slepenkin, Sara B E Andersson, Jonas H Fagerberg, Christel A S Bergström, Ellena M Peterson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4214720?pdf=render
id doaj-5fa51311598a47578bc6f308764c4d7d
record_format Article
spelling doaj-5fa51311598a47578bc6f308764c4d7d2020-11-25T01:43:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11091810.1371/journal.pone.0110918Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.Christian PedersenAnatoly SlepenkinSara B E AnderssonJonas H FagerbergChristel A S BergströmEllena M PetersonThe salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infection the SA compound INP0341, when dissolved in a liquid, was able to significantly protect mice from a vaginal infection with C. trachomatis. To expand upon this finding, in this report INP0341 was formulated as a vaginal gel, suitable for use in humans. Gelling agents (polymers) with inherent antimicrobial properties were chosen to maximize the total antimicrobial effect of the gel. In vitro formulation work generated a gel with suitable rheology and sustained drug release. A formulation containing 1 mM INP0341, 1.6 wt% Cremophor ELP (solubility enhancer) and 1.5 wt% poly(acrylic acid) (gelling and antimicrobial agent), was chosen for studies of efficacy and toxicity using a mouse model of a vaginal infection. The gel formulation was able to attenuate a vaginal challenge with C. trachomatis, serovar D. Formulations with and without INP0341 afforded protection, but the inclusion of INP0341 increased the protection. Mouse vaginal tissue treated with the formulation showed no indication of gel toxicity. The lack of toxicity was confirmed by in vitro assays using EpiVaginal tissues, which showed that a 24 h exposure to the gel formulation did not decrease the cell viability or the barrier function of the tissue. Therefore, the gel formulation described here appears to be a promising vaginal microbicide to prevent a C. trachomatis infection with the potential to be expanded to other sexually transmitted diseases.http://europepmc.org/articles/PMC4214720?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Christian Pedersen
Anatoly Slepenkin
Sara B E Andersson
Jonas H Fagerberg
Christel A S Bergström
Ellena M Peterson
spellingShingle Christian Pedersen
Anatoly Slepenkin
Sara B E Andersson
Jonas H Fagerberg
Christel A S Bergström
Ellena M Peterson
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
PLoS ONE
author_facet Christian Pedersen
Anatoly Slepenkin
Sara B E Andersson
Jonas H Fagerberg
Christel A S Bergström
Ellena M Peterson
author_sort Christian Pedersen
title Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
title_short Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
title_full Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
title_fullStr Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
title_full_unstemmed Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
title_sort formulation of the microbicide inp0341 for in vivo protection against a vaginal challenge by chlamydia trachomatis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description The salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infection the SA compound INP0341, when dissolved in a liquid, was able to significantly protect mice from a vaginal infection with C. trachomatis. To expand upon this finding, in this report INP0341 was formulated as a vaginal gel, suitable for use in humans. Gelling agents (polymers) with inherent antimicrobial properties were chosen to maximize the total antimicrobial effect of the gel. In vitro formulation work generated a gel with suitable rheology and sustained drug release. A formulation containing 1 mM INP0341, 1.6 wt% Cremophor ELP (solubility enhancer) and 1.5 wt% poly(acrylic acid) (gelling and antimicrobial agent), was chosen for studies of efficacy and toxicity using a mouse model of a vaginal infection. The gel formulation was able to attenuate a vaginal challenge with C. trachomatis, serovar D. Formulations with and without INP0341 afforded protection, but the inclusion of INP0341 increased the protection. Mouse vaginal tissue treated with the formulation showed no indication of gel toxicity. The lack of toxicity was confirmed by in vitro assays using EpiVaginal tissues, which showed that a 24 h exposure to the gel formulation did not decrease the cell viability or the barrier function of the tissue. Therefore, the gel formulation described here appears to be a promising vaginal microbicide to prevent a C. trachomatis infection with the potential to be expanded to other sexually transmitted diseases.
url http://europepmc.org/articles/PMC4214720?pdf=render
work_keys_str_mv AT christianpedersen formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
AT anatolyslepenkin formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
AT sarabeandersson formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
AT jonashfagerberg formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
AT christelasbergstrom formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
AT ellenampeterson formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis
_version_ 1725033311053545472